Research programme: corticotropin releasing factor R1 receptor antagonists - sanofi-aventis
Alternative Names: SSR 126374Latest Information Update: 17 Mar 2009
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Corticotropin-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 17 Mar 2009 No development reported - Preclinical for Anxiety disorders in France (unspecified route)
- 17 Mar 2009 No development reported - Preclinical for Depression in France (unspecified route)
- 09 Feb 2006 Preclinical trials in Anxiety disorders in France (unspecified route)